Raftis, Emma JDelday, Margaret ICowie, PhilipMcCluskey, Seánín MSingh, Mark DEttorre, AnnaMulder, Imke E2018-08-302018-08-302018-08-13Raftis, E J, Delday, M I, Cowie, P, McCluskey, S M, Singh, M D, Ettorre, A & Mulder, I E 2018, 'Bifidobacterium breve MRx0004 protects against airway inflammation in a severe asthma model by suppressing both neutrophil and eosinophil lung infiltration', Scientific Reports, vol. 8, 12024. https://doi.org/10.1038/s41598-018-30448-z2045-2322PubMedCentral: PMC6089914http://hdl.handle.net/2164/11016All authors were employees of (or in the case of MID, seconded full-time to) 4D Pharma Research Ltd while engaged in the research project. This work was supported by funding provided by 4D Pharma PLC. 4D Pharma Research Ltd owns a family of patent applications which are pending internationally which are derived from International Patent Publication No. WO2016/203223 which protect the treatment of severe asthma using MRx0004. George Grant, Angela Patterson, Imke Mulder, Seanin McCluskey and Emma Raftis are named as inventors for this patent family. The authors declare no other competing interests.2230067engSDG 3 - Good Health and Well-beingJournal ArticleR MedicineRJournal article10.1038/s41598-018-30448-z8